Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms
König C, Kuti J
PHARMACOTHERAPY. 2024;44(8):658-674.

Pretomanid-resistant tuberculosis
Koehler N, Andres S, Merker M, Dreyer V, John A, Kuhns M, Krieger D, Choong E, Verougstraete N, Zur Wiesch P, Wicha S, König C, Kalsdorf B, Sanchez Carballo P, Schaub D, Werngren J, Schön T, Peloquin C, Schönfeld N, Verstraete A, Decosterd L, Aarnoutse R, Niemann S, Maurer F, Lange C
J INFECTION. 2023;86(5):520-524.

A Single-Run HPLC-MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant Tuberculosis
Köhler N, Karaköse H, Grobbel H, Hillemann D, Andres S, König C, Kalsdorf B, Brehm T, Böttcher L, Friesen I, Hoffmann H, Strelec D, Schaub D, Peloquin C, Schmiedel S, Decosterd L, Choong E, Wicha S, Aarnoutse R, Lange C, Sánchez Carballo P
PHARMACEUTICS. 2023;15(11):2543.

Posaconazole exposure in critically ill ICU patients: a need for action
König C, Göpfert M, Kluge S, Wichmann D
INFECTION. 2023;51(6):1767-1772.

Cerebrospinal fluid penetration of fosfomycin in patients with ventriculitis: an observational study
König C, Martens-Lobenhoffer J, Czorlich P, Westphal M, Bode-Böger S, Kluge S, Grensemann J
ANN CLIN MICROB ANTI. 2023;22(1):29.

Acute-on-chronic liver failure alters linezolid pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
Tikiso T, Fuhrmann V, König C, Jarczak D, Iwersen-Bergmann S, Kluge S, Wicha S, Grensemann J
ANN INTENSIVE CARE. 2023;13(1):83.

Ciprofloxacin in Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): A Population Pharmacokinetic Study
Alihodzic D, Wicha S, Frey O, König C, Baehr M, Jarczak D, Kluge S, Langebrake C
PHARMACEUTICS. 2022;14(5):.

The impact of pharmacists' interventions within the Closed Loop Medication Management process on medication safety: An analysis in a German university hospital
Berger V, Sommer C, Boje P, Hollmann J, Hummelt J, König C, Lezius S, van der Linde A, Marhenke C, Melzer S, Michalowski N, Baehr M, Langebrake C
FRONT PHARMACOL. 2022;13:.

Correction to: Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial
Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T, Hohn A, Weigand M, Michels G, Kluge S, Nierhaus A, Jarczak D, König C, Weismann D, Frey O, Witzke D, Müller C, Bauer M, Kiehntopf M, Neugebauer S, Lehmann T, Roberts J, Pletz M
INTENS CARE MED. 2022;48(5):646-647.

Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial
Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T, Hohn A, Weigand M, Michels G, Kluge S, Nierhaus A, Jarczak D, König C, Weismann D, Frey O, Witzke D, Müller C, Bauer M, Kiehntopf M, Neugebauer S, Lehmann T, Roberts J, Pletz M
INTENS CARE MED. 2022;48(3):311-321.

A dosing nomograph for cerebrospinal fluid penetration of meropenem applied by continuous infusion in patients with nosocomial ventriculitis
König C, Grensemann J, Czorlich P, Schlemm E, Kluge S, Wicha S
CLIN MICROBIOL INFEC. 2022;28(7):1022.e9-1022.e16.

Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages
Royzman D, Peckert-Maier K, Stich L, König C, Wild A, Tauchi M, Ostalecki C, Kiesewetter F, Seyferth S, Lee G, Eming S, Fuchs M, Kunz M, Stürmer E, Peters E, Berking C, Zinser E, Steinkasserer A
FRONT IMMUNOL. 2022;13:.

Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study
Grensemann J, Pfaffendorf C, Wicha S, Koenig C, Roedl K, Jarczak D, Iwersen-Bergmann S, Manthey C, Kluge S, Fuhrmann V
MICROORGANISMS. 2021;9(10):2087.

Die pharmakologische/pharmazeutische Visite in der Intensivmedizin
Hilgarth H, Baehr M, Kluge S, König C
MED KLIN-INTENSIVMED. 2021;116(2):173-184.

Clinically Relevant Interactions with Anti-Infectives on Intensive Care Units—A Multicenter Delphi Study
Koeck J, Hilgarth H, Ameln-Mayerhofer A, Meyn D, Warlich R, Münstedt A, Horn D, Koenig C
ANTIBIOTICS-BASEL. 2021;10(11):.

Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance
König C, Both A, Rohde H, Kluge S, Frey O, Röhr A, Wichmann D
ANTIBIOTICS-BASEL. 2021;10(6):649.

Correction: König et al. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance. Antibiotics 2021, 10, 649
König C, Both A, Rohde H, Kluge S, Frey O, Röhr A, Wichmann D
ANTIBIOTICS-BASEL. 2021;10(10):.

Pharmacokinetics of meropenem during advanced organ support (ADVOS®) and continuous renal replacement therapy
König C, Kluge S, Fuhrmann V, Jarczak D
INT J ARTIF ORGANS. 2021;44(10):783-786.

The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: Data from the multinational SMARRT Study
Roberts J, Joynt G, Lee A, Choi G, Bellomo R, Kanji S, Mudaliar M, Peake S, Stephens D, Taccone F, Ulldemolins M, Valkonen M, Agbeve J, Baptista J, Bekos V, Boidin C, Brinkmann A, Buizen L, Castro P, Cole C, Creteur J, De Waele J, Deans R, Eastwood G, Escobar L, Gomersall C, Gresham R, Jamal J, Kluge S, König C, Koulouras V, Lassig-Smith M, Laterre P, Lei K, Leung P, Lefrant J, Llauradó-Serra M, Martin-Loeches I, Mat Nor M, Ostermann M, Parker S, Rello J, Roberts D, Roberts M, Richards B, Rodríguez A, Roehr A, Roger C, Seoane L, Sinnollareddy M, Sousa E, Soy D, Spring A, Starr T, Thomas J, Turnidge J, Wallis S, Williams T, Wittebole X, Zikou X, Paul S, Lipman J
CLIN INFECT DIS. 2021;72(8):1369-1378.

Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Cefiderocol
Zimmer J, Röhr A, Kluge S, Faller J, Frey O, Wichmann D, König C
ANTIBIOTICS-BASEL. 2021;10(3):242.

Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
Grensemann J, Busse D, König C, Roedl K, Jäger W, Jarczak D, Iwersen-Bergmann S, Manthey C, Kluge S, Kloft C, Fuhrmann V
ANN INTENSIVE CARE. 2020;10(1):48.

Therapeutisches Drug Monitoring von Antiinfektiva bei Intensivpatienten – für welche Arzneistoffe und wie?
König C, Kluge S, Wicha S
DEUT MED WOCHENSCHR. 2020;145(24):1764-1769.

Medikamentengabe und allgemeine Komplikationen bei extrakorporalen Verfahren
Brinkmann A, Bürle M, Frey O, König C, Richter D, Röhr A, Träger K
2019. Handbuch Extrakorporale Organunterstützung. Geldner G, Alscher M (eds.). 1. ed. München: Elsevier GmbH, 7-38.

Reply from the authors to 'In vitro removal of anti-infective agents by a novel cytokine adsorbent system'
König C
INT J ARTIF ORGANS. 2019;42(9):531-533.

In vitro removal of anti-infective agents by a novel cytokine adsorbent system
König C, Röhr A, Frey O, Brinkmann A, Roberts J, Wichmann D, Braune S, Kluge S, Nierhaus A
INT J ARTIF ORGANS. 2019;42(2):57-64.

Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharamcokinetic study
Braune S, König C, Roberts J, Nierhaus A, Steinmetz O, Baehr M, Kluge S, Langebrake C
CRIT CARE. 2018;22(1):25-34.

Adäquate Antiinfektivatherapie: Bedeutung der individuellen Dosierung und Applikation
Brinkmann A, Röhr A, Köberer A, Fuchs T, Krüger W, König C, Richter D, Weigand M, Frey O
ANAESTHESIST. 2018;67(6):461-476.

Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy
Economou C, Kielstein J, Czock D, Xie J, Field J, Richards B, Tallot M, Visser A, Koenig C, Hafer C, Schmidt J, Lipman J, Roberts J
INT J ANTIMICROB AG. 2018;52(2):151-157.

Carbapenem-resistant Gram-negative pathogens in a German university medical Center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations
Katchanov J, Asar L, Klupp E, Both A, Rothe C, König C, Rohde H, Kluge S, Maurer F
PLOS ONE. 2018;13(4):e0195757.

Intrathecal penetration of meropenem and vancomycin administered by continuous infusion in patients suffering from ventriculitis-a retrospective analysis
Mader M, Czorlich P, König C, Fuhrmann V, Kluge S, Westphal M, Grensemann J
ACTA NEUROCHIR. 2018;160(11):2099-2105.

Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate
Both A, Büttner H, Huang J, Perbandt M, Belmar Campos C, Christner M, Maurer F, Kluge S, König C, Aepfelbacher M, Wichmann D, Rohde H
J ANTIMICROB CHEMOTH. 2017;72(9):2483-2488.

Risk factors for excessively prolonged meropenem use in the intensive care settinga case-contol study
Katchanov J, Kreuels B, Maurer F, Wöstmann K, Jochum J, König C, Seoudy K, Rohde H, Lohse A, Wichmann D, Baehr M, Rothe C, Kluge S
BMC INFECT DIS. 2017;17(1):131.

Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis
König C, Braune S, Roberts J, Nierhaus A, Steinmetz O, Baehr M, Frey O, Langebrake C, Kluge S
J ANTIMICROB CHEMOTH. 2017;72(5):1433-1440.

Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates
Klupp E, Both A, Belmar Campos C, Büttner H, König C, Christopeit M, Christner M, Aepfelbacher M, Rohde H
EUR J CLIN MICROBIOL. 2016;35(12):1957-1961.

Letzte Aktualisierung aus dem FIS: 11.12.2024 - 05:27 Uhr